Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...

Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Telehealth company Hims & Hers Health (NYSE:HIMS) announced in Q4 CY2024, with sales up 95.1% year on year to $481.1 million.

Hims&Hers Health Inc (NYSE:HIMS) reported weaker-than-expected fourth-quarter earnings that overshadowed the telehealth company's revenue that topped Wall Street estimates.

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...